HRP20100693T1 - Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora - Google Patents
Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora Download PDFInfo
- Publication number
- HRP20100693T1 HRP20100693T1 HR20100693T HRP20100693T HRP20100693T1 HR P20100693 T1 HRP20100693 T1 HR P20100693T1 HR 20100693 T HR20100693 T HR 20100693T HR P20100693 T HRP20100693 T HR P20100693T HR P20100693 T1 HRP20100693 T1 HR P20100693T1
- Authority
- HR
- Croatia
- Prior art keywords
- azonia
- bicyclo
- hydroxy
- octane bromide
- acetoxy
- Prior art date
Links
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 title 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 title 1
- 150000008584 quinuclidines Chemical class 0.000 title 1
- -1 9H-fluoren-9-yl Chemical group 0.000 claims abstract 27
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 22
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 16
- 239000001257 hydrogen Substances 0.000 claims abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 10
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims abstract 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000005842 heteroatom Chemical group 0.000 claims abstract 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000001301 oxygen Chemical group 0.000 claims abstract 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- 229910052717 sulfur Chemical group 0.000 claims abstract 8
- 239000011593 sulfur Chemical group 0.000 claims abstract 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 7
- 125000005843 halogen group Chemical group 0.000 claims abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 2
- PTHNRUQVXLGKKT-WTHDWRSPSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CC(=O)NC=1C=CON=1 PTHNRUQVXLGKKT-WTHDWRSPSA-N 0.000 claims abstract 2
- KVYFPKJRJWDXCT-LWOCSEGBSA-O [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CC(=O)NC1=CN=CC=N1 KVYFPKJRJWDXCT-LWOCSEGBSA-O 0.000 claims abstract 2
- ZPFCXHFVCOFWOZ-XTBFPHCZSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CC(=O)NC1=CC=NC=N1 ZPFCXHFVCOFWOZ-XTBFPHCZSA-N 0.000 claims abstract 2
- 239000012907 medicinal substance Substances 0.000 claims 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 229940124630 bronchodilator Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- PWSXXTLDLCIUGO-UTEXUTGQSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 PWSXXTLDLCIUGO-UTEXUTGQSA-N 0.000 claims 2
- NVQBJTIINOFPEC-OFIQDHIESA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=NC=NC=N1 NVQBJTIINOFPEC-OFIQDHIESA-N 0.000 claims 2
- DQWQUUWAYXIMGT-ZVPZRTFFSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 DQWQUUWAYXIMGT-ZVPZRTFFSA-N 0.000 claims 2
- CFMGCNDIOKQGHM-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 CFMGCNDIOKQGHM-AYFIPJBYSA-N 0.000 claims 2
- SLCAXYRZANJZTL-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CC=N1 SLCAXYRZANJZTL-SGFHCSRJSA-N 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 230000000954 anitussive effect Effects 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 229940124584 antitussives Drugs 0.000 claims 2
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 claims 1
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- MXTHDVYBJMKRAW-TWBGCDCQSA-N [(2r)-2-methyl-1-[(5-methyl-1,2-oxazol-3-yl)carbamoyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide Chemical compound [Br-].C1([C@H]([N+]2(CCC1CC2)C(=O)NC1=NOC(C)=C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 MXTHDVYBJMKRAW-TWBGCDCQSA-N 0.000 claims 1
- LBHUBPVFRVTKRE-NJSXXHIRSA-N [(3R)-1-[2-amino-1-(1,2-oxazol-3-yl)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate phosphate Chemical compound [O-]P([O-])([O-])=O.C1CC([C@H](C2)OC(=O)[C@@](O)(C3CCCC3)C=3C=CC=CC=3)CC[N+]12C(C(=O)N)C=1C=CON=1.C1CC([C@H](C2)OC(=O)[C@@](O)(C3CCCC3)C=3C=CC=CC=3)CC[N+]12C(C(=O)N)C=1C=CON=1.C1CC([C@H](C2)OC(=O)[C@@](O)(C3CCCC3)C=3C=CC=CC=3)CC[N+]12C(C(=O)N)C=1C=CON=1 LBHUBPVFRVTKRE-NJSXXHIRSA-N 0.000 claims 1
- NDKPGOIGMAPCKZ-ADFHNETRSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 NDKPGOIGMAPCKZ-ADFHNETRSA-N 0.000 claims 1
- CZDAJDIMEGEBST-UXJVTRAKSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21C(=O)NC1=CC=CN=N1 CZDAJDIMEGEBST-UXJVTRAKSA-N 0.000 claims 1
- PPDAIKJPFBAEPV-BDVUIUMHSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21C(=O)NC1=CC=CN=N1 PPDAIKJPFBAEPV-BDVUIUMHSA-N 0.000 claims 1
- WOZUKJBPTBJMRI-AYFIPJBYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 WOZUKJBPTBJMRI-AYFIPJBYSA-N 0.000 claims 1
- ASIIWQLNQRMJJF-BDVUIUMHSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 ASIIWQLNQRMJJF-BDVUIUMHSA-N 0.000 claims 1
- MDRKZBWOEKSIQL-ZVPZRTFFSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 MDRKZBWOEKSIQL-ZVPZRTFFSA-N 0.000 claims 1
- HKJJONBLZRQIOO-AYFIPJBYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 HKJJONBLZRQIOO-AYFIPJBYSA-N 0.000 claims 1
- HOYHGTSNECKWMY-BDVUIUMHSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 HOYHGTSNECKWMY-BDVUIUMHSA-N 0.000 claims 1
- SZIQGRZMRQJLJF-PKPSOOLGSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 SZIQGRZMRQJLJF-PKPSOOLGSA-N 0.000 claims 1
- KGSIOSOOXZMXFH-SFZOXUKMSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C1=COC=C1)(O)C1CCCC1 KGSIOSOOXZMXFH-SFZOXUKMSA-N 0.000 claims 1
- GAZDVSXUYQWHSZ-QVOXVMGDSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 GAZDVSXUYQWHSZ-QVOXVMGDSA-N 0.000 claims 1
- DZCKMHXNWKSWTB-PKPSOOLGSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 DZCKMHXNWKSWTB-PKPSOOLGSA-N 0.000 claims 1
- YVFLUJNRTOMJLQ-UXJVTRAKSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21C(=O)NC1=CC=CN=N1 YVFLUJNRTOMJLQ-UXJVTRAKSA-N 0.000 claims 1
- UESPJDKHOUCQCC-BDVUIUMHSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21C(=O)NC1=CC=CN=N1 UESPJDKHOUCQCC-BDVUIUMHSA-N 0.000 claims 1
- CHLFOCRTPQDCQG-SGFHCSRJSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 CHLFOCRTPQDCQG-SGFHCSRJSA-N 0.000 claims 1
- GKTUUSSQPLEKSD-SGFHCSRJSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 GKTUUSSQPLEKSD-SGFHCSRJSA-N 0.000 claims 1
- ZDNIVRNFHOJTJA-PMLWWUNYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 ZDNIVRNFHOJTJA-PMLWWUNYSA-N 0.000 claims 1
- IVYCCLOHYSTYRR-PMLWWUNYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 IVYCCLOHYSTYRR-PMLWWUNYSA-N 0.000 claims 1
- WASPVIDRFWKIFH-PMLWWUNYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3C4=CC=CC=C4C4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 WASPVIDRFWKIFH-PMLWWUNYSA-N 0.000 claims 1
- IINGMDFVUYFQHG-PMLWWUNYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 IINGMDFVUYFQHG-PMLWWUNYSA-N 0.000 claims 1
- XTOAYDTZDJBLAL-RSYCBKOKSA-N [(3r)-1-[1-(1,2-oxazol-3-ylamino)-1-oxopropan-2-yl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C(O)(C=3C=CC=CC=3)C=3C=CC=CC=3)CC[N+]12C(C)C(=O)NC=1C=CON=1 XTOAYDTZDJBLAL-RSYCBKOKSA-N 0.000 claims 1
- JCPYBEFKFGQQBW-DMWRAEOSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)[N+]21CC(=O)NC=1C=CON=1 JCPYBEFKFGQQBW-DMWRAEOSSA-N 0.000 claims 1
- LYEUZKSCFWFFMP-OFIQDHIESA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(2-chlorophenyl)-2-hydroxyacetate;bromide Chemical group [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3C(=CC=CC=3)Cl)C=3C(=CC=CC=3)Cl)[N+]21CC(=O)NC=1C=CON=1 LYEUZKSCFWFFMP-OFIQDHIESA-N 0.000 claims 1
- JXEBVFQBPQIYOH-FKYYSRDKSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC=1C=CON=1 JXEBVFQBPQIYOH-FKYYSRDKSA-N 0.000 claims 1
- HZGHGUPFITZHEX-GXVQUIFISA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-diphenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC1=NOC=C1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 HZGHGUPFITZHEX-GXVQUIFISA-N 0.000 claims 1
- QNGBQXNPFDMABV-WULMZJJMSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-diphenylpropanoate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(C)(C=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 QNGBQXNPFDMABV-WULMZJJMSA-N 0.000 claims 1
- HLXFHYCWWFUOSC-IULAOUEKSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(2-chlorophenyl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3C=CC=CC=3)C=3C(=CC=CC=3)Cl)[N+]21CC(=O)NC=1C=CON=1 HLXFHYCWWFUOSC-IULAOUEKSA-N 0.000 claims 1
- DOFPJTZAWLYUGW-FIQQBEOASA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 DOFPJTZAWLYUGW-FIQQBEOASA-N 0.000 claims 1
- QURMEKJIUAZANR-FVRMQZBVSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclobutyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCC1 QURMEKJIUAZANR-FVRMQZBVSA-N 0.000 claims 1
- JKNHJSSAZYNMIW-FIQQBEOASA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 JKNHJSSAZYNMIW-FIQQBEOASA-N 0.000 claims 1
- JBYALQATTNNXLM-ROILBPFPSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 JBYALQATTNNXLM-ROILBPFPSA-N 0.000 claims 1
- UYDZCDBOKNTCDY-NSLDKZMESA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 UYDZCDBOKNTCDY-NSLDKZMESA-N 0.000 claims 1
- MUNWNMDXVFWWSJ-FIQQBEOASA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 MUNWNMDXVFWWSJ-FIQQBEOASA-N 0.000 claims 1
- BQJVDKLIOBNQRU-JMYPFRHISA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C1=COC=C1)(O)C1CCCC1 BQJVDKLIOBNQRU-JMYPFRHISA-N 0.000 claims 1
- IPYXMSOXADDKER-SUSCGCCGSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 IPYXMSOXADDKER-SUSCGCCGSA-N 0.000 claims 1
- PFNWPHKQGJNTSN-UTEXUTGQSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 PFNWPHKQGJNTSN-UTEXUTGQSA-N 0.000 claims 1
- GUOWKYWHJRLGRT-VTTAHNPLSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopropyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1SC=CC=1)(O)C1CC1 GUOWKYWHJRLGRT-VTTAHNPLSA-N 0.000 claims 1
- GUHYQPHICDOZIV-DMWRAEOSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-ethylsulfanyl-2,2-diphenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(SCC)(C=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 GUHYQPHICDOZIV-DMWRAEOSSA-N 0.000 claims 1
- XFDIKUJEOXYVQO-PKLCTQDOSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-bis(3-methoxyphenyl)acetate;bromide Chemical compound [Br-].COC1=CC=CC(C(O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=C(OC)C=CC=2)=C1 XFDIKUJEOXYVQO-PKLCTQDOSA-N 0.000 claims 1
- JASBHIMHORBWBD-PKLCTQDOSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-bis(4-methoxyphenyl)acetate;bromide Chemical compound [Br-].C1=CC(OC)=CC=C1C(O)(C=1C=CC(OC)=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 JASBHIMHORBWBD-PKLCTQDOSA-N 0.000 claims 1
- LMVPTKHKZQNMTP-DMWRAEOSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-bis(4-methylphenyl)acetate;bromide Chemical compound [Br-].C1=CC(C)=CC=C1C(O)(C=1C=CC(C)=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 LMVPTKHKZQNMTP-DMWRAEOSSA-N 0.000 claims 1
- KQZGFLAOVMRBJE-FKYYSRDKSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC=1C=CON=1 KQZGFLAOVMRBJE-FKYYSRDKSA-N 0.000 claims 1
- KNRAZWQROOQZCD-HIPLPVRDSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-(2-methoxyphenyl)-2-phenylacetate;bromide Chemical compound [Br-].COC1=CC=CC=C1C(O)(C=1C=CC=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 KNRAZWQROOQZCD-HIPLPVRDSA-N 0.000 claims 1
- SQKMLNPPWDJIOV-KNNDMWINSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-(2-methylphenyl)-2-phenylacetate;bromide Chemical compound [Br-].CC1=CC=CC=C1C(O)(C=1C=CC=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 SQKMLNPPWDJIOV-KNNDMWINSA-N 0.000 claims 1
- UKIGHUJEPXNYAZ-HIPLPVRDSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-(4-methoxyphenyl)-2-phenylacetate;bromide Chemical compound [Br-].C1=CC(OC)=CC=C1C(O)(C=1C=CC=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 UKIGHUJEPXNYAZ-HIPLPVRDSA-N 0.000 claims 1
- VTBLMPHPICFVKP-FIQQBEOASA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 VTBLMPHPICFVKP-FIQQBEOASA-N 0.000 claims 1
- QJIBWXVASULUCW-WULMZJJMSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-methoxy-2,2-diphenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(OC)(C=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 QJIBWXVASULUCW-WULMZJJMSA-N 0.000 claims 1
- DAKBDLXZFNNQTD-RTDUGLMJSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC=1C=CON=1 DAKBDLXZFNNQTD-RTDUGLMJSA-N 0.000 claims 1
- IDKPHFMVEHJQHS-RTDUGLMJSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC=1C=CON=1 IDKPHFMVEHJQHS-RTDUGLMJSA-N 0.000 claims 1
- BZWAIILYUZPDDF-YUXMWEGSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4C4=CC=CC=C43)CC[N+]12CC(=O)NC=1C=CON=1 BZWAIILYUZPDDF-YUXMWEGSSA-N 0.000 claims 1
- ZLXHOBGHKNOVHH-YUXMWEGSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC=1C=CON=1 ZLXHOBGHKNOVHH-YUXMWEGSSA-N 0.000 claims 1
- YPNWAUAZEBXEDV-DXLVBJHUSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=COC=C2)C2=COC=C2)=N1 YPNWAUAZEBXEDV-DXLVBJHUSA-N 0.000 claims 1
- YSLCOKGCOCSEPO-WQKGMRGTSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(2-chlorophenyl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C(=CC=CC=2)Cl)=N1 YSLCOKGCOCSEPO-WQKGMRGTSA-N 0.000 claims 1
- ILKKYAURZDXSSS-OANMHNKXSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=COC=C2)C=2C=CC=CC=2)=N1 ILKKYAURZDXSSS-OANMHNKXSA-N 0.000 claims 1
- UTLGONQMBRVFOI-PBYMMPLCSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclobutyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCC2)C=2SC=CC=2)=N1 UTLGONQMBRVFOI-PBYMMPLCSA-N 0.000 claims 1
- LTWYADDGFGLFLX-OANMHNKXSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCCC2)C2=CSC=C2)=N1 LTWYADDGFGLFLX-OANMHNKXSA-N 0.000 claims 1
- ACHOBFNJGCSMLX-HLESCNFNSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCC2)C2=COC=C2)=N1 ACHOBFNJGCSMLX-HLESCNFNSA-N 0.000 claims 1
- PSIHJGFSCZDQJM-HLESCNFNSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCC2)C2=CSC=C2)=N1 PSIHJGFSCZDQJM-HLESCNFNSA-N 0.000 claims 1
- QVPAEXCVBGXRLP-DXLVBJHUSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=CSC=C2)C2=CSC=C2)=N1 QVPAEXCVBGXRLP-DXLVBJHUSA-N 0.000 claims 1
- RCVVTPNGORUHNV-OANMHNKXSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=CSC=C2)C=2C=CC=CC=2)=N1 RCVVTPNGORUHNV-OANMHNKXSA-N 0.000 claims 1
- JNSNUESJPBPJFB-XCEOWTAJSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3CC3=CC=CC=C32)=N1 JNSNUESJPBPJFB-XCEOWTAJSA-N 0.000 claims 1
- JYGVFVNWVFASAH-XCEOWTAJSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3CC3=CC=CC=C32)=N1 JYGVFVNWVFASAH-XCEOWTAJSA-N 0.000 claims 1
- BFZONOOZVKTCME-CJYZSSDISA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3OC3=CC=CC=C32)=N1 BFZONOOZVKTCME-CJYZSSDISA-N 0.000 claims 1
- XAPIRXONNQLWIT-CJYZSSDISA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3C3=CC=CC=C32)=N1 XAPIRXONNQLWIT-CJYZSSDISA-N 0.000 claims 1
- DEDIGANFAOGJEA-CJYZSSDISA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3OC3=CC=CC=C32)=N1 DEDIGANFAOGJEA-CJYZSSDISA-N 0.000 claims 1
- HXEXVYRMUSSNCH-ZJKFLMFHSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3C=CC3=CC=CC=C32)=N1 HXEXVYRMUSSNCH-ZJKFLMFHSA-N 0.000 claims 1
- UJEGNJDPSAYEKZ-FKBRAVIBSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=COC=C2)C2=COC=C2)=N1 UJEGNJDPSAYEKZ-FKBRAVIBSA-N 0.000 claims 1
- WTQSSEGZNBJVOB-VYIGTOTHSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(2-chlorophenyl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C(=CC=CC=2)Cl)=N1 WTQSSEGZNBJVOB-VYIGTOTHSA-N 0.000 claims 1
- JOMHYNAWONELCA-SUSCGCCGSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=COC=C2)C=2C=CC=CC=2)=N1 JOMHYNAWONELCA-SUSCGCCGSA-N 0.000 claims 1
- RJKIEYOHIQSNMU-UTEXUTGQSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclobutyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCC2)C=2SC=CC=2)=N1 RJKIEYOHIQSNMU-UTEXUTGQSA-N 0.000 claims 1
- VFEGPHAWGSNMOD-SUSCGCCGSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCCC2)C2=COC=C2)=N1 VFEGPHAWGSNMOD-SUSCGCCGSA-N 0.000 claims 1
- YNFBYINXTBJLAC-SUSCGCCGSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCCC2)C2=CSC=C2)=N1 YNFBYINXTBJLAC-SUSCGCCGSA-N 0.000 claims 1
- WIQJVHQRIJIIIT-NSLDKZMESA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCC2)C=2OC=CC=2)=N1 WIQJVHQRIJIIIT-NSLDKZMESA-N 0.000 claims 1
- DRJQIJVVNXCFIL-FIQQBEOASA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCC2)C2=COC=C2)=N1 DRJQIJVVNXCFIL-FIQQBEOASA-N 0.000 claims 1
- RLIHYEQLMBPUPE-FVRMQZBVSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopropyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CC2)C=2SC=CC=2)=N1 RLIHYEQLMBPUPE-FVRMQZBVSA-N 0.000 claims 1
- YBQUOFVNBMCGCF-FKBRAVIBSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=CSC=C2)C2=CSC=C2)=N1 YBQUOFVNBMCGCF-FKBRAVIBSA-N 0.000 claims 1
- GHWDLGZAQGDKCA-SUSCGCCGSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=CSC=C2)C=2C=CC=CC=2)=N1 GHWDLGZAQGDKCA-SUSCGCCGSA-N 0.000 claims 1
- BAJKRLDRJMTAPQ-PKLCTQDOSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3CC3=CC=CC=C32)=N1 BAJKRLDRJMTAPQ-PKLCTQDOSA-N 0.000 claims 1
- HSRJLUDXMMAKFW-PKLCTQDOSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3CC3=CC=CC=C32)=N1 HSRJLUDXMMAKFW-PKLCTQDOSA-N 0.000 claims 1
- ORONXPJTLSUYAG-RTDUGLMJSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3OC3=CC=CC=C32)=N1 ORONXPJTLSUYAG-RTDUGLMJSA-N 0.000 claims 1
- USIMCYSRHQZCOQ-RTDUGLMJSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3C3=CC=CC=C32)=N1 USIMCYSRHQZCOQ-RTDUGLMJSA-N 0.000 claims 1
- DKCODRXMQIFZBL-RTDUGLMJSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3OC3=CC=CC=C32)=N1 DKCODRXMQIFZBL-RTDUGLMJSA-N 0.000 claims 1
- RKGNQYRWOANOMP-FKEZYDJSSA-N [(3r)-1-[2-amino-2-oxo-1-(1,3,5-triazin-2-yl)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)CC[N+]12C(C(=O)N)C1=NC=NC=N1 RKGNQYRWOANOMP-FKEZYDJSSA-N 0.000 claims 1
- FWBDUQHLLIWQPZ-NSOJYXMXSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=NC=NC=N1 FWBDUQHLLIWQPZ-NSOJYXMXSA-N 0.000 claims 1
- GGSBTIUOMADSDN-YSAQQSICSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=NC=NC=N1 GGSBTIUOMADSDN-YSAQQSICSA-N 0.000 claims 1
- XBHHWDUIBLQRJI-NOWPHXOYSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 XBHHWDUIBLQRJI-NOWPHXOYSA-N 0.000 claims 1
- NWBVZKXXTJBIMK-YSAQQSICSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 NWBVZKXXTJBIMK-YSAQQSICSA-N 0.000 claims 1
- ILVLVFWRALKHCJ-DFUUOGHFSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 ILVLVFWRALKHCJ-DFUUOGHFSA-N 0.000 claims 1
- OBLKUAOGTWYWDH-NOWPHXOYSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 OBLKUAOGTWYWDH-NOWPHXOYSA-N 0.000 claims 1
- PYCJKYAGHQMPCB-YSAQQSICSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 PYCJKYAGHQMPCB-YSAQQSICSA-N 0.000 claims 1
- XEFQMFZTUHWAAO-KMIFLNSOSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 XEFQMFZTUHWAAO-KMIFLNSOSA-N 0.000 claims 1
- CHEJEFSNPMQJRZ-YHRORWFSSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 CHEJEFSNPMQJRZ-YHRORWFSSA-N 0.000 claims 1
- NUSSSVNHXDWJET-KMIFLNSOSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 NUSSSVNHXDWJET-KMIFLNSOSA-N 0.000 claims 1
- RSRZRXSREIBLKA-UXHKZPOWSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCC1 RSRZRXSREIBLKA-UXHKZPOWSA-N 0.000 claims 1
- NYNBJOURLGSFHV-NSOJYXMXSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=NC=NC=N1 NYNBJOURLGSFHV-NSOJYXMXSA-N 0.000 claims 1
- NEWXOMFLRSEFQU-YSAQQSICSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=NC=NC=N1 NEWXOMFLRSEFQU-YSAQQSICSA-N 0.000 claims 1
- DEODHGSTQZRJAR-OASTYHRRSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC1=NC=NC=N1 DEODHGSTQZRJAR-OASTYHRRSA-N 0.000 claims 1
- HBDHQNASIFJDMR-OASTYHRRSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=NC=NC=N1 HBDHQNASIFJDMR-OASTYHRRSA-N 0.000 claims 1
- SSEUVGQKRYVPBR-OFIQDHIESA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CC(=O)NC1=NC=NC=N1 SSEUVGQKRYVPBR-OFIQDHIESA-N 0.000 claims 1
- QNJOKWDGICCMGR-OFIQDHIESA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=NC=NC=N1 QNJOKWDGICCMGR-OFIQDHIESA-N 0.000 claims 1
- XTQWLMJWVILPLV-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=CN=CC=N1 XTQWLMJWVILPLV-WHPWLWEVSA-N 0.000 claims 1
- WFHLUCIMTYUEBR-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CN=CC=N1 WFHLUCIMTYUEBR-QVOXVMGDSA-N 0.000 claims 1
- GZNVXBRNMFONBM-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 GZNVXBRNMFONBM-YGXSZZIWSA-N 0.000 claims 1
- VTFGHQOKBDCJRA-WNCQOFSISA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 VTFGHQOKBDCJRA-WNCQOFSISA-N 0.000 claims 1
- GDIDDJZPLUFRLC-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 GDIDDJZPLUFRLC-YGXSZZIWSA-N 0.000 claims 1
- YYFZLFYVXCVDIT-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 YYFZLFYVXCVDIT-QVOXVMGDSA-N 0.000 claims 1
- HLKWSDNOBXLJTF-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCC1 HLKWSDNOBXLJTF-BDVUIUMHSA-N 0.000 claims 1
- QLMOJOJZOMDMNW-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=CN=CC=N1 QLMOJOJZOMDMNW-WHPWLWEVSA-N 0.000 claims 1
- MEWVUKMLGXIVMX-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CN=CC=N1 MEWVUKMLGXIVMX-QVOXVMGDSA-N 0.000 claims 1
- ZCIMJCILQZIZTC-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CC=N1 ZCIMJCILQZIZTC-LNORMHFUSA-N 0.000 claims 1
- LJNYWXYTSQSFRH-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CC=N1 LJNYWXYTSQSFRH-LNORMHFUSA-N 0.000 claims 1
- KELKXMKWBZVARH-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CC=N1 KELKXMKWBZVARH-SGFHCSRJSA-N 0.000 claims 1
- WUJYVHUCCLKWKW-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4C4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CC=N1 WUJYVHUCCLKWKW-SGFHCSRJSA-N 0.000 claims 1
- BXAQTQSNHWPVFY-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CC=N1 BXAQTQSNHWPVFY-SGFHCSRJSA-N 0.000 claims 1
- PDGAHRBJCQCRPZ-XLKOHVDKSA-N [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)[N+]21CC(=O)NC1=CC=CC=N1 PDGAHRBJCQCRPZ-XLKOHVDKSA-N 0.000 claims 1
- DZIZKRWZUCSZLP-ROILBPFPSA-N [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CC=CC=N1 DZIZKRWZUCSZLP-ROILBPFPSA-N 0.000 claims 1
- DLBQMPBEOZQBAY-NVJOYBRVSA-N [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=CC=CC=N1 DLBQMPBEOZQBAY-NVJOYBRVSA-N 0.000 claims 1
- IMZUFXGEXYQVPC-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=NC=CC=N1 IMZUFXGEXYQVPC-WHPWLWEVSA-N 0.000 claims 1
- CDBOJSYPKSLCAQ-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 CDBOJSYPKSLCAQ-YGXSZZIWSA-N 0.000 claims 1
- HWBRWDLMEZLCFM-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 HWBRWDLMEZLCFM-QVOXVMGDSA-N 0.000 claims 1
- PEFOWOYEHBJITF-WNCQOFSISA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 PEFOWOYEHBJITF-WNCQOFSISA-N 0.000 claims 1
- PTXMAWMLZHIOEP-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 PTXMAWMLZHIOEP-YGXSZZIWSA-N 0.000 claims 1
- HMGQOEGPGTXZLJ-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 HMGQOEGPGTXZLJ-AYFIPJBYSA-N 0.000 claims 1
- PUTZVIMHMIDAJN-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCC1 PUTZVIMHMIDAJN-BDVUIUMHSA-N 0.000 claims 1
- UHNAGLQQLRRVGH-ZVPZRTFFSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 UHNAGLQQLRRVGH-ZVPZRTFFSA-N 0.000 claims 1
- LQSPCDHPVNKHMN-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 LQSPCDHPVNKHMN-AYFIPJBYSA-N 0.000 claims 1
- HUIUSUAROAOBLQ-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCC1 HUIUSUAROAOBLQ-BDVUIUMHSA-N 0.000 claims 1
- VNHVFUQTCCGRTQ-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=NC=CC=N1 VNHVFUQTCCGRTQ-WHPWLWEVSA-N 0.000 claims 1
- DIWDICYHMOAPRL-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=NC=CC=N1 DIWDICYHMOAPRL-QVOXVMGDSA-N 0.000 claims 1
- YZPBSTOKTIAJRI-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC1=NC=CC=N1 YZPBSTOKTIAJRI-LNORMHFUSA-N 0.000 claims 1
- HLASKHSYFAXUIS-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=NC=CC=N1 HLASKHSYFAXUIS-SGFHCSRJSA-N 0.000 claims 1
- HUEDRJVKOUXUAU-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=NC=CC=N1 HUEDRJVKOUXUAU-SGFHCSRJSA-N 0.000 claims 1
- XRUYSILIWCNGBE-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=CC=NC=N1 XRUYSILIWCNGBE-WHPWLWEVSA-N 0.000 claims 1
- OEYHQTXLMJHSOB-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CC=NC=N1 OEYHQTXLMJHSOB-QVOXVMGDSA-N 0.000 claims 1
- NJFVAMNYKFYERH-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 NJFVAMNYKFYERH-YGXSZZIWSA-N 0.000 claims 1
- VBIYLYUWXZELLQ-WNCQOFSISA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 VBIYLYUWXZELLQ-WNCQOFSISA-N 0.000 claims 1
- HYHOFJXUEWBJOB-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 HYHOFJXUEWBJOB-QVOXVMGDSA-N 0.000 claims 1
- PUOMOFCXVAAXCE-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 PUOMOFCXVAAXCE-AYFIPJBYSA-N 0.000 claims 1
- FUGGBRBLEUYEIP-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCC1 FUGGBRBLEUYEIP-BDVUIUMHSA-N 0.000 claims 1
- QGJDAWHXJGNHNS-ZVPZRTFFSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 QGJDAWHXJGNHNS-ZVPZRTFFSA-N 0.000 claims 1
- NINFWSUPOJXCOM-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 NINFWSUPOJXCOM-AYFIPJBYSA-N 0.000 claims 1
- WRRCJHMXWXUJAD-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCC1 WRRCJHMXWXUJAD-BDVUIUMHSA-N 0.000 claims 1
- DFGHFDKLUVABAW-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=CC=NC=N1 DFGHFDKLUVABAW-WHPWLWEVSA-N 0.000 claims 1
- DDJBAJDWPDCKNP-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CC=NC=N1 DDJBAJDWPDCKNP-QVOXVMGDSA-N 0.000 claims 1
- KELOTVXGBURWDT-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CC=NC=N1 KELOTVXGBURWDT-LNORMHFUSA-N 0.000 claims 1
- BASRJFATTNGULG-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=CC=NC=N1 BASRJFATTNGULG-LNORMHFUSA-N 0.000 claims 1
- GBFGPOWJLPODQG-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=CC=NC=N1 GBFGPOWJLPODQG-SGFHCSRJSA-N 0.000 claims 1
- VPSQEXUYUGDHSR-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CC=NC=N1 VPSQEXUYUGDHSR-SGFHCSRJSA-N 0.000 claims 1
- DGNMUQUXQWLGQN-WWAPZXQFSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CN=C1 DGNMUQUXQWLGQN-WWAPZXQFSA-N 0.000 claims 1
- QSQDXNCTHMRZPS-DXLVBJHUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=CN=CN=C1 QSQDXNCTHMRZPS-DXLVBJHUSA-N 0.000 claims 1
- CXNXVWKVLHDHJZ-AVRGKSJGSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CN=CN=C1 CXNXVWKVLHDHJZ-AVRGKSJGSA-N 0.000 claims 1
- IBFHCPMNGCRVGP-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 IBFHCPMNGCRVGP-QVOXVMGDSA-N 0.000 claims 1
- XRHXDEOWHHDRGS-AVRGKSJGSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 XRHXDEOWHHDRGS-AVRGKSJGSA-N 0.000 claims 1
- SJLLTBPMESHADM-CXEAGMIJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 SJLLTBPMESHADM-CXEAGMIJSA-N 0.000 claims 1
- YIHPGYTUXLBQJB-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 YIHPGYTUXLBQJB-QVOXVMGDSA-N 0.000 claims 1
- BRILMVBXECABEL-AVRGKSJGSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 BRILMVBXECABEL-AVRGKSJGSA-N 0.000 claims 1
- CBCSMHWZCBFINO-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 CBCSMHWZCBFINO-BDVUIUMHSA-N 0.000 claims 1
- UYFKNXVQKKUIIT-FGXDWOATSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCC1 UYFKNXVQKKUIIT-FGXDWOATSA-N 0.000 claims 1
- RVZBZXKTDZTEDW-AFHFFQAUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 RVZBZXKTDZTEDW-AFHFFQAUSA-N 0.000 claims 1
- DUYCENKMMAZWNR-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 DUYCENKMMAZWNR-BDVUIUMHSA-N 0.000 claims 1
- DMFLXIOETUDIRP-DXLVBJHUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=CN=CN=C1 DMFLXIOETUDIRP-DXLVBJHUSA-N 0.000 claims 1
- DQHCQNAXJMUYBD-AVRGKSJGSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CN=CN=C1 DQHCQNAXJMUYBD-AVRGKSJGSA-N 0.000 claims 1
- BYBFJHNMVLBVBU-XCEOWTAJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CN=C1 BYBFJHNMVLBVBU-XCEOWTAJSA-N 0.000 claims 1
- XPXSBGICJHODQB-CJYZSSDISA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CN=C1 XPXSBGICJHODQB-CJYZSSDISA-N 0.000 claims 1
- LOGKHQPVIHNRQC-CJYZSSDISA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CN=C1 LOGKHQPVIHNRQC-CJYZSSDISA-N 0.000 claims 1
- SZUGBQXPVVBDJC-CJYZSSDISA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4C4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CN=C1 SZUGBQXPVVBDJC-CJYZSSDISA-N 0.000 claims 1
- HBHKKIXTJCXTEU-CJYZSSDISA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CN=C1 HBHKKIXTJCXTEU-CJYZSSDISA-N 0.000 claims 1
- KVRBYPPMUIHVSM-NXCMLHJESA-N [(3r)-1-[2-oxo-2-[(4-phenyl-1,2-oxazol-3-yl)amino]ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C(=CON=2)C=2C=CC=CC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 KVRBYPPMUIHVSM-NXCMLHJESA-N 0.000 claims 1
- KWOSOGIXVROBEO-RSYBFYOOSA-N [O-]P([O-])([O-])=O.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1 Chemical compound [O-]P([O-])([O-])=O.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1 KWOSOGIXVROBEO-RSYBFYOOSA-N 0.000 claims 1
- PWFMLWUCJBKRTI-IVPFZVFJSA-N [O-]P([O-])([O-])=O.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1 Chemical compound [O-]P([O-])([O-])=O.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1 PWFMLWUCJBKRTI-IVPFZVFJSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 239000011630 iodine Chemical group 0.000 claims 1
- 229910052740 iodine Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0424284.8A GB0424284D0 (en) | 2004-11-02 | 2004-11-02 | Organic compounds |
| PCT/EP2005/011662 WO2006048225A1 (en) | 2004-11-02 | 2005-10-31 | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100693T1 true HRP20100693T1 (hr) | 2011-01-31 |
Family
ID=33515948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100693T HRP20100693T1 (hr) | 2004-11-02 | 2010-12-14 | Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7723356B2 (sk) |
| EP (2) | EP2206499A1 (sk) |
| JP (1) | JP4950896B2 (sk) |
| KR (1) | KR101252307B1 (sk) |
| CN (1) | CN101056634B (sk) |
| AR (1) | AR054090A1 (sk) |
| AT (1) | ATE481099T1 (sk) |
| AU (1) | AU2005300710B2 (sk) |
| BR (1) | BRPI0517945A (sk) |
| CA (1) | CA2583237C (sk) |
| CY (1) | CY1110952T1 (sk) |
| DE (1) | DE602005023639D1 (sk) |
| DK (1) | DK1811999T3 (sk) |
| EC (1) | ECSP077424A (sk) |
| ES (1) | ES2353142T3 (sk) |
| GB (1) | GB0424284D0 (sk) |
| HR (1) | HRP20100693T1 (sk) |
| IL (1) | IL182695A0 (sk) |
| JO (1) | JO2613B1 (sk) |
| MA (1) | MA29080B1 (sk) |
| MX (1) | MX2007005189A (sk) |
| MY (1) | MY145207A (sk) |
| NO (1) | NO20072371L (sk) |
| NZ (1) | NZ554302A (sk) |
| PE (1) | PE20060609A1 (sk) |
| PL (1) | PL1811999T3 (sk) |
| PT (1) | PT1811999E (sk) |
| RU (1) | RU2399620C2 (sk) |
| SI (1) | SI1811999T1 (sk) |
| TN (1) | TNSN07164A1 (sk) |
| TW (1) | TW200628154A (sk) |
| WO (1) | WO2006048225A1 (sk) |
| ZA (1) | ZA200702772B (sk) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR044134A1 (es) | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| US7994211B2 (en) | 2005-08-08 | 2011-08-09 | Argenta Discovery Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
| EP1940775A2 (en) | 2005-08-11 | 2008-07-09 | University of Massachusetts | Methods and compositions for the efficient delivery of therapeutic agents to cells and animals |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| SI2094694T1 (sl) * | 2006-11-14 | 2011-04-29 | Astrazeneca Ab | Kiniklidinski derivati (hetero)arilcikloheptankarboksilne kisline kot muskarinski receptorski antagonisti |
| JP4604129B2 (ja) * | 2006-12-19 | 2010-12-22 | アストラゼネカ・アクチエボラーグ | ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体 |
| CA2697752C (en) | 2007-09-07 | 2016-01-26 | Theravance, Inc. | Guanidine-containing compounds useful as muscarinic receptor antagonists |
| EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| BRPI0906838A2 (pt) | 2008-01-11 | 2015-07-14 | Novartis Ag | Pirimidinas como inibidores de quinase |
| CN102908624A (zh) * | 2008-05-13 | 2013-02-06 | 阿斯利康(瑞典)有限公司 | 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 |
| CN102089304A (zh) * | 2008-05-13 | 2011-06-08 | 阿斯利康(瑞典)有限公司 | 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物 |
| GB0808708D0 (en) * | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| GB0808707D0 (en) * | 2008-05-13 | 2008-06-18 | Argenta Discovery Ltd | New compounds 275 |
| US20090326004A1 (en) * | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0811100D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination |
| WO2009153536A1 (en) * | 2008-06-17 | 2009-12-23 | Argenta Discovery Limited | 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| EP2206712A1 (en) * | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
| CN102388021B (zh) | 2009-04-09 | 2015-02-18 | 诺华股份有限公司 | 吡咯烷鎓盐的制备方法 |
| KR20130111968A (ko) * | 2010-06-22 | 2013-10-11 | 키에시 파르마슈티시 엣스. 피. 에이. | 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물 |
| BR112012032330A2 (pt) * | 2010-06-22 | 2016-11-08 | Chiesi Farma Spa | formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン |
| JP2011195593A (ja) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| KR20150095888A (ko) | 2012-12-19 | 2015-08-21 | 노파르티스 아게 | 오토탁신 억제제 |
| EP3134398A1 (en) | 2014-04-24 | 2017-03-01 | Novartis Ag | Autotaxin inhibitors |
| CA3193201A1 (en) * | 2014-05-06 | 2015-11-12 | Anthony G. Visco | Methods of treating or preventing preterm labor |
| CN109851615B (zh) * | 2019-04-22 | 2021-06-08 | 上海旭东海普药业有限公司 | 纯化戊乙奎醚的方法 |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833592A (en) | 1966-05-31 | 1974-09-03 | Little Inc A | Tropanyl alpha,alpha-diphenyl-alpha-fluoroacetate esters |
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8916480D0 (en) | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
| AU677776B2 (en) | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| JP3192424B2 (ja) | 1992-04-02 | 2001-07-30 | スミスクライン・ビーチャム・コーポレイション | アレルギーまたは炎症疾患の治療用化合物 |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9617730D0 (en) | 1996-08-23 | 1996-10-02 | Pfizer Ltd | Quarternary ammonium compounds |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| GB9723589D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723566D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| PE20000270A1 (es) | 1998-02-14 | 2000-05-20 | Glaxo Group Ltd | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813565D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| YU81100A (sh) | 1998-06-23 | 2003-10-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4 diola |
| WO2000000531A1 (en) | 1998-06-30 | 2000-01-06 | The Dow Chemical Company | Polymer polyols and a process for the production thereof |
| CA2347512C (en) | 1998-10-16 | 2005-12-06 | Pfizer Inc. | Adenine derivatives |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
| GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| CZ20023537A3 (cs) | 2000-04-27 | 2003-02-12 | Boehringer Ingelheim Pharma Kg | Betamimetika, způsob jejich výroby a použití jako farmaceutický prostředek |
| TWI227240B (en) | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
| GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| ATE260277T1 (de) * | 2000-06-27 | 2004-03-15 | S A L V A T Lab Sa | Von arylalkylaminen abgeleitete carbamate |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| OA12394A (en) | 2000-08-05 | 2004-07-09 | Glaxo Group Ltd | 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent. |
| WO2002016356A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| JP2004506735A (ja) | 2000-08-18 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用キヌクリジン置換アリール化合物 |
| AU2001282873A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| WO2002017358A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| AU2001282910A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |
| WO2002015662A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| SK8002003A3 (en) | 2000-12-22 | 2004-05-04 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| US6476222B2 (en) | 2001-01-05 | 2002-11-05 | Sun Chemical Corporation | Preparation of heat stable pigment violet 23 |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
| EP2039700A2 (en) | 2001-04-30 | 2009-03-25 | Glaxo Group Limited | Novel anti-inflammatory androstane derivatives |
| IL158774A0 (en) | 2001-05-25 | 2004-05-12 | Pfizer | An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases |
| ATE399174T1 (de) | 2001-06-12 | 2008-07-15 | Glaxo Group Ltd | Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen |
| PT1425001E (pt) | 2001-09-14 | 2009-02-18 | Glaxo Group Ltd | Derivados de fenetanolamina para o tratamento de doenças respiratórias |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| WO2003048181A1 (en) | 2001-12-01 | 2003-06-12 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| MXPA04006206A (es) | 2001-12-20 | 2004-12-06 | S A L V A T Lab Sa | Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico. |
| WO2003072592A1 (en) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| AU2003201693A1 (en) | 2002-01-21 | 2003-09-02 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| US7268152B2 (en) | 2002-03-26 | 2007-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| MXPA04009329A (es) | 2002-03-26 | 2005-01-25 | Boehringer Ingelheim Pharma | Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y usos de los mismos. |
| JP2006515829A (ja) | 2002-04-10 | 2006-06-08 | ユニバーシティ オブ バージニア パテント ファウンデーション | 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用 |
| DE60335869D1 (de) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
| US7271197B2 (en) | 2002-04-25 | 2007-09-18 | Glaxo Group Limited | Phenethanolamine derivatives |
| EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP1517895B1 (en) | 2002-06-25 | 2007-03-14 | Merck Frosst Canada Ltd. | 8-(biaryl) quinoline pde4 inhibitors |
| EP1519922A1 (en) | 2002-07-02 | 2005-04-06 | Merck Frosst Canada & Co. | Di-aryl-substituted ethane pyridone pde4 inhibitors |
| WO2004005229A1 (en) | 2002-07-08 | 2004-01-15 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| PL373597A1 (en) | 2002-08-10 | 2005-09-05 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| PL373146A1 (en) | 2002-08-10 | 2005-08-22 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
| MXPA05001354A (es) | 2002-08-10 | 2005-04-28 | Altana Pharma Ag | Piperidina-ftalazonas sustituidas por pirrolidinodiona como inhibidores pde4. |
| WO2004018431A2 (en) | 2002-08-17 | 2004-03-04 | Altana Pharma Ag | Novel phenanthridines |
| PL373598A1 (en) | 2002-08-17 | 2005-09-05 | Altana Pharma Ag | Novel benzonaphthyridines |
| AU2003259747A1 (en) | 2002-08-21 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| RS20050174A (en) | 2002-08-29 | 2007-06-04 | Boehringer Ingelheim Pharmaceuticals Inc., | -3(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases |
| DE60310576T2 (de) | 2002-08-29 | 2007-10-31 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer |
| ATE353217T1 (de) | 2002-08-29 | 2007-02-15 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| JP4520309B2 (ja) | 2002-09-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体 |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| EA200500618A1 (ru) | 2002-10-11 | 2005-12-29 | Пфайзер Инк. | Производные индола в качестве бета-2 агонистов |
| EP1554264B1 (en) | 2002-10-22 | 2007-08-08 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| ATE380185T1 (de) | 2002-10-23 | 2007-12-15 | Glenmark Pharmaceuticals Ltd | Tricyclische verbindungen zur behandlung von entzündlichen- und allergischen erkrankungen: verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| AU2003286143A1 (en) | 2002-10-28 | 2004-05-13 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| US7732432B2 (en) | 2003-01-21 | 2010-06-08 | Merck Sharp & Dohme Corp. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| EP1615881A2 (en) | 2003-04-01 | 2006-01-18 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| JP4516064B2 (ja) | 2003-04-04 | 2010-08-04 | ノバルティス アーゲー | 気道疾患の処置のためのキノリン−２−オン誘導体 |
| AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| US7358244B2 (en) | 2003-05-28 | 2008-04-15 | Theravance, Inc. | Azabicycloalkane compounds |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| ES2298757T3 (es) | 2003-06-04 | 2008-05-16 | Pfizer Inc. | Derivados de z-amino-piridina como agonistas de adrecorreceptores beta-2. |
| DE10332239B3 (de) | 2003-07-16 | 2005-03-03 | Framatome Anp Gmbh | Zirkoniumlegierung und Bauteile für den Kern von leichtwassergekühlten Kernreaktoren |
| WO2005033121A2 (en) | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
| GB0323701D0 (en) | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
| US7736490B2 (en) | 2003-12-19 | 2010-06-15 | Shell Oil Company | Systems, methods, and catalysts for producing a crude product |
| DE102004001413A1 (de) | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| ES2239546B1 (es) * | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
| UY28871A1 (es) | 2004-04-27 | 2005-11-30 | Glaxo Group Ltd | Antagonistas del receptor de acetilcolina muscarinico |
| ES2246170B1 (es) | 2004-07-29 | 2007-04-01 | Almirall Prodesfarma, S.A. | Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio. |
-
2004
- 2004-11-02 GB GBGB0424284.8A patent/GB0424284D0/en not_active Ceased
-
2005
- 2005-10-12 JO JOP/2005/0145A patent/JO2613B1/ar active
- 2005-10-24 MY MYPI20054966A patent/MY145207A/en unknown
- 2005-10-31 AT AT05798470T patent/ATE481099T1/de active
- 2005-10-31 WO PCT/EP2005/011662 patent/WO2006048225A1/en active Application Filing
- 2005-10-31 CA CA2583237A patent/CA2583237C/en not_active Expired - Fee Related
- 2005-10-31 SI SI200531188T patent/SI1811999T1/sl unknown
- 2005-10-31 RU RU2007120454/04A patent/RU2399620C2/ru not_active IP Right Cessation
- 2005-10-31 MX MX2007005189A patent/MX2007005189A/es active IP Right Grant
- 2005-10-31 AU AU2005300710A patent/AU2005300710B2/en not_active Ceased
- 2005-10-31 NZ NZ554302A patent/NZ554302A/en not_active IP Right Cessation
- 2005-10-31 CN CN2005800380673A patent/CN101056634B/zh not_active Expired - Fee Related
- 2005-10-31 PE PE2005001274A patent/PE20060609A1/es not_active Application Discontinuation
- 2005-10-31 EP EP10156591A patent/EP2206499A1/en not_active Withdrawn
- 2005-10-31 BR BRPI0517945-9A patent/BRPI0517945A/pt not_active IP Right Cessation
- 2005-10-31 KR KR1020077009938A patent/KR101252307B1/ko not_active IP Right Cessation
- 2005-10-31 EP EP05798470A patent/EP1811999B1/en active Active
- 2005-10-31 DK DK05798470.0T patent/DK1811999T3/da active
- 2005-10-31 PT PT05798470T patent/PT1811999E/pt unknown
- 2005-10-31 DE DE602005023639T patent/DE602005023639D1/de active Active
- 2005-10-31 JP JP2007538352A patent/JP4950896B2/ja not_active Expired - Fee Related
- 2005-10-31 ES ES05798470T patent/ES2353142T3/es active Active
- 2005-10-31 AR ARP050104547A patent/AR054090A1/es not_active Application Discontinuation
- 2005-10-31 US US11/577,417 patent/US7723356B2/en not_active Expired - Fee Related
- 2005-10-31 PL PL05798470T patent/PL1811999T3/pl unknown
- 2005-11-01 TW TW094138292A patent/TW200628154A/zh unknown
-
2007
- 2007-04-03 ZA ZA200702772A patent/ZA200702772B/xx unknown
- 2007-04-19 IL IL182695A patent/IL182695A0/en unknown
- 2007-04-27 EC EC2007007424A patent/ECSP077424A/es unknown
- 2007-04-30 TN TNP2007000164A patent/TNSN07164A1/fr unknown
- 2007-05-08 NO NO20072371A patent/NO20072371L/no not_active Application Discontinuation
- 2007-05-30 MA MA29952A patent/MA29080B1/fr unknown
-
2010
- 2010-03-11 US US12/721,897 patent/US8084463B2/en not_active Expired - Fee Related
- 2010-11-25 CY CY20101101081T patent/CY1110952T1/el unknown
- 2010-12-14 HR HR20100693T patent/HRP20100693T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100693T1 (hr) | Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora | |
| ES2710556T3 (es) | Compuesto inhibidor de Trk | |
| ES2337241T3 (es) | Derivados de piperazina con actividad antagonista de receptores ccr1. | |
| CN106573006A (zh) | 作为药物的rip1激酶抑制剂杂环酰胺 | |
| TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
| MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
| WO2021150885A1 (en) | Cannabinoid derivatives | |
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| EP3022201A1 (en) | Autotaxin inhibitors | |
| JP2023539614A (ja) | アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物 | |
| CN103402995A (zh) | 新型吲哚、吲唑衍生物或其盐 | |
| CN113164490A (zh) | 采用p2x3拮抗剂治疗瘙痒症 | |
| GB2516138A (en) | The treatment of inflammatory disorders | |
| Uto | 1, 2-Benzisoxazole compounds: a patent review (2009–2014) | |
| JP2514163B2 (ja) | ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物 | |
| AU2018347447B2 (en) | Methods and compositions for treating pruritus, xerosis, and associated disease using CCR3-inhibitors | |
| JP2015534990A (ja) | 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法 | |
| SA05260389B1 (ar) | فينيل ببرازين تجمع بين الميل إلى مستقبلات دوبامين d2- ومواضع اعادة امتصاص السيروتونين | |
| WO2021186180A1 (en) | Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii | |
| CS277691A3 (en) | 3-/1h-indazol-3-yl/-4-pyridinamines, process and intermediates for their preparation and their application as medicaments | |
| EP4211129A1 (en) | Thiophenoxime and furanoxime scaffolds | |
| EP3134398A1 (en) | Autotaxin inhibitors | |
| JPH02279673A (ja) | キノロン誘導体 | |
| TH65078A (th) | อนุพันธ์ไพร์โรลิดีนออกซาไดอะโซล-และไทอะไดอะโซล |